Advancing the Path of National Production

According to Atra Zist Aray’s Public Relations Office, the official introduction ceremony of “Luxafill Hailow” was held with a scientific and professional approach. The event brought together prominent professors, specialists, and professionals from the fields of medicine and biotechnology, who engaged in technical discussions and shared insights about the company’s newest innovation.

A Scientific Approach to Innovation

Dr. Ali Faraji, CEO of Atra Zist Aray, emphasized that under the current national circumstances, the company’s priority has been to foster a scientific platform for in‑depth evaluation of Luxafill Hailow. He highlighted that knowledge-based organizations have a national responsibility to maintain industrial activity and sustain technological innovation even amidst challenging times.

Therefore, the introduction of Luxafill Hailow was presented as a scientific meeting rather than a festive event—reflecting Atra Zist Aray’s commitment to quality, continuous improvement, and knowledge-driven development.

Luxafill Hailow: Injectable Hydrogel — Domestic Production Rooted in R&D

Dr. Faraji further praised the dedication of the company’s staff during difficult days, noting that Luxafill Hailow represents the result of young Iranian expertise and national technological investment.

Atra Zist Aray is among the few biotechnology firms in Iran conducting the production process entirely in-house—from concept to completion. Limited reliance on imported raw materials and a strong focus on domestic R&D are among the company’s key strengths. With this product launch, the previously announced expansion of the product portfolio has entered a new operational phase.

Progress in Toxin Technology Transfer

Another important topic highlighted during the symposium was the technology transfer of toxin production. Dr. Faraji announced that negotiations with Atabay Company (Turkey) began last year, followed by a technical visit of the Atabay team to Iran in March. Installation of new equipment for the production line is currently in progress — marking a significant milestone in the development of advanced biotechnology capabilities in the country.

Scientific assessments conducted at Ankara University have confirmed that the locally produced toxin shows comparable potency and performance to international reference products. This validation provides a strong foundation for continuing the localization of toxin manufacturing technology in Iran.

Atra Zist Aray’s Entry into Tehran Stock Exchange

The CEO also highlighted the company’s landmark entry into Tehran Stock Exchange (TSE) on 19 November 2025, becoming the first biotechnology firm listed under the symbol “DATRA.”

As outlined in the company’s prospectus, the consistent launch of new products has been a strategic commitment — and the introduction of Luxafill Hailow aligns perfectly with that roadmap.

Luxafill Hailow’s Position in the Product Portfolio

Although the product was ready for market release earlier, its official unveiling was postponed due to national circumstances. Luxafill Hailow is now presented to academics and medical professionals to collect scientific feedback for further enhancement.

Atra Zist Aray continues to focus on producing knowledge-based, competitive-quality cosmeceuticals that meet high scientific and clinical standards. Luxafill Hailow has been designed specifically to meet domestic demand while ensuring internationally compliant quality.

Future Programs and Outlook

The CEO also announced the upcoming launch of a Vitamin C Serum by the end of the current year and continued expansion of the Luxafill brand into new segments next year.

The company remains committed to sustained biotechnology-based product development, deeper domestic production, and technological advancement — reinforcing its role as a driving force within Iran’s biotechnology industry.

Conclusion

The unveiling of Luxafill Hailow reflects Atra Zist Aray’s scientific and strategic approach towards locally-driven R&D and advanced technology transfer. From local production and product portfolio expansion to toxin technology localization and public listing under the symbol “DATRA,” Atra Zist Aray continues to strengthen its position as one of the leading players in Iran’s biotechnology sector.

This product launch marks a significant step forward in the company’s long-term mission to drive innovation, quality, and growth in domestic biocosmeceutical production.